LOCALLY ADVANCED SOLID TUMOR
Clinical trials for LOCALLY ADVANCED SOLID TUMOR explained in plain language.
Never miss a new study
Get alerted when new LOCALLY ADVANCED SOLID TUMOR trials appear
Sign up with your email to follow new studies for LOCALLY ADVANCED SOLID TUMOR, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New targeted pill shows promise for hard-to-treat ROS1 cancers
Disease control Recruiting nowThis study tests a new drug called zidesamtinib (NVL-520) in people with advanced lung cancer or other solid tumors that have a specific genetic change called ROS1. The goal is to find the best dose and see how well the drug shrinks tumors. About 359 adults will take part, and th…
Matched conditions: LOCALLY ADVANCED SOLID TUMOR
Phase: PHASE1, PHASE2 • Sponsor: Nuvalent Inc. • Aim: Disease control
Last updated May 26, 2026 03:21 UTC
-
New hope for ALK-Positive cancers: targeted drug NVL-655 enters key trials
Disease control Recruiting nowThis study tests a new drug called NVL-655 in people with advanced ALK-positive lung cancer or other solid tumors. The goal is to find the best dose and see how well it shrinks tumors. About 840 adults will take part, and the drug is taken as a pill.
Matched conditions: LOCALLY ADVANCED SOLID TUMOR
Phase: PHASE1, PHASE2 • Sponsor: Nuvalent Inc. • Aim: Disease control
Last updated May 26, 2026 03:15 UTC
-
New radioactive drug targets Hard-to-Treat tumors in early trial
Disease control Recruiting nowThis study is testing an experimental radioactive drug called 177Lu-SN201 in people with advanced solid tumors that have not responded to standard treatments or for which no standard treatment exists. The drug is designed to deliver radiation directly to tumors. The main goals ar…
Matched conditions: LOCALLY ADVANCED SOLID TUMOR
Phase: PHASE1, PHASE2 • Sponsor: Spago Nanomedical AB • Aim: Disease control
Last updated May 26, 2026 03:13 UTC
-
New pill targets hard-to-treat lung cancer mutation
Disease control Recruiting nowThis early-stage study tests an experimental drug called NVL-330 in people with advanced lung cancer that has specific changes in the HER2 gene. The main goals are to find a safe dose and see if the drug can shrink tumors. About 200 adults with this type of lung cancer will take …
Matched conditions: LOCALLY ADVANCED SOLID TUMOR
Phase: PHASE1 • Sponsor: Nuvalent Inc. • Aim: Disease control
Last updated May 26, 2026 03:12 UTC
-
New drug targets Hard-to-Treat cancers with missing gene
Disease control Recruiting nowThis study tests a new oral drug, TNG462, in people with advanced solid tumors that have a specific genetic deletion (MTAP). The goal is to find the safest dose and see if the drug can shrink or slow tumor growth, either alone or with another drug. About 225 adults with various c…
Matched conditions: LOCALLY ADVANCED SOLID TUMOR
Phase: PHASE1, PHASE2 • Sponsor: Tango Therapeutics, Inc. • Aim: Disease control
Last updated May 22, 2026 13:50 UTC
-
New injection shows promise for Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new drug called IPN60300 in adults with advanced solid tumors that have spread or not responded to standard treatments. The goal is to find the safest and most effective dose and to see if the drug can shrink tumors. All participants receive the drug by injecti…
Matched conditions: LOCALLY ADVANCED SOLID TUMOR
Phase: PHASE1, PHASE2 • Sponsor: Ipsen • Aim: Disease control
Last updated May 18, 2026 12:06 UTC
-
New drug FOG-001 targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis study tests a new drug, FOG-001, in about 595 people with advanced solid tumors that have not responded to other treatments. The goal is to see if FOG-001 is safe and can shrink tumors or slow their growth. The trial focuses on several cancer types, including colorectal, pro…
Matched conditions: LOCALLY ADVANCED SOLID TUMOR
Phase: PHASE1, PHASE2 • Sponsor: Parabilis Medicines, Inc. • Aim: Disease control
Last updated May 11, 2026 20:46 UTC
-
New scan could reveal how well immunotherapy is working
Diagnosis Recruiting nowThis study tests a special imaging agent (89Zr-Df-crefmirlimab) that helps PET scans show immune cells called CD8 T cells inside tumors. About 30 adults with advanced solid cancers will receive this agent before and during standard immunotherapy (PD-1 antibody). The goal is to se…
Matched conditions: LOCALLY ADVANCED SOLID TUMOR
Phase: PHASE2 • Sponsor: University Medical Center Groningen • Aim: Diagnosis
Last updated May 20, 2026 11:53 UTC
-
New radiation technique aims to shrink bulky tumors
Symptom relief Recruiting nowThis study tests a special type of radiation called lattice therapy for people with large, hard-to-treat tumors. The goal is to see if it can shrink tumors better and with fewer side effects than standard radiation. About 37 adults with advanced solid tumors will receive this tre…
Matched conditions: LOCALLY ADVANCED SOLID TUMOR
Phase: PHASE2 • Sponsor: University of Cincinnati • Aim: Symptom relief
Last updated May 26, 2026 03:11 UTC
-
Cream may ease rash side effect of cancer drugs
Symptom relief Recruiting nowThis study tests whether a tretinoin cream can prevent or reduce the acne-like rash that often occurs as a side effect of certain cancer drugs (panitumumab or cetuximab). About 25 adults with advanced solid tumors will apply the cream to one side of their face and a placebo to th…
Matched conditions: LOCALLY ADVANCED SOLID TUMOR
Phase: PHASE2 • Sponsor: University of Utah • Aim: Symptom relief
Last updated May 22, 2026 13:53 UTC